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Abstract
Mitochondrial myopathy (MM) with progressive external ophthal-
moplegia (PEO) is a common manifestation of mitochondrial
disease in adulthood, for which there is no curative therapy. In
mice with MM, ketogenic diet significantly delayed progression of
the disease. We asked in this pilot study what effects high-fat,
low-carbohydrate “modified Atkins” diet (mAD) had for PEO/MM
patients and control subjects and followed up the effects by clini-
cal, morphological, transcriptomic, and metabolomic analyses. All
of our five patients, irrespective of genotype, showed a subacute
response after 1.5–2 weeks of diet, with progressive muscle pain
and leakage of muscle enzymes, leading to premature discontinua-
tion of the diet. Analysis of muscle ultrastructure revealed selec-
tive fiber damage, especially in the ragged-red-fibers (RRFs), a MM
hallmark. Two years of follow-up showed improvement of muscle
strength, suggesting activation of muscle regeneration. Our results
indicate that (i) nutrition can modify mitochondrial disease
progression, (ii) dietary counseling should be part of MM care, (iii)
short mAD is a tool to induce targeted RRF lysis, and (iv) mAD, a
common weight-loss method, may induce muscle damage in a
population subgroup.
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Introduction
Mitochondrial disorders are among the most common inherited
metabolic diseases affecting approximately 1 in 2,000–5,000 individ-
uals (Skladal et al, 2003; Thorburn, 2004). These disorders are most
often caused by dysfunction of the oxidative phosphorylation
(OXPHOS) system, which comprises the enzymes of the respiratory
chain (RC) and the ATP synthase embedded in the inner mitochon-
drial membrane. These molecular micromachines transform the
nutrient energy to ATP, the common energy currency of cells. RC
deficiency can be caused by mutations in nuclear genes, encoding
proteins involved in RC synthesis, assembly, structure, or mainte-
nance, or by primary mutations of mitochondrial DNA (mtDNA).
Progressive external ophthalmoplegia (PEO) is a common manifes-
tation of adult-onset mitochondrial myopathy (MM), often caused
by sporadic heteroplasmic single deletions, point mutations of
mtDNA, or multiple mtDNA deletions caused secondarily by muta-
tion of nuclear genes involved in mtDNA maintenance (Ylikallio &
Suomalainen, 2012). MM manifests typically in the early adulthood,
with progressive ptosis, ophthalmoplegia, and exercise intolerance
(Zeviani et al, 1989). Many patients benefit from palliative care,
including surgical blepharoplasty, but no curative treatments exist.
Low-carbohydrate ketogenic diet has been utilized to treat refrac-
tory epilepsies in children and has also been shown to reduce
seizures in individuals with mitochondrial disease (Kang et al,
2007; Joshi et al, 2009). It also has been evaluated as a therapy for
metabolic syndrome and type 2 diabetes, while a form of ketogenic
diet, Atkins diet, is used widely for weight loss (for a review, see
Paoli et al, 2013). The diet reduces blood glucose and improves
insulin responses and lipid profiles in healthy adults (Westman
et al, 2002) as well as in diabetic individuals (Gumbiner et al, 1996;
Boden et al, 2005) and has been considered relatively safe.
1 Research Program of Molecular Neurology, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
2 Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
3 Obesity Research Unit, Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland
4 Metabolomics Unit, Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
5 Department of Radiology, University of Helsinki and HUS Radiology, Helsinki Medical Imaging Center, Helsinki, Finland
6 Department of Clinical Physiology and Nuclear Medicine, Laboratory of Clinical Physiology, Helsinki University Hospitals, Helsinki, Finland
7 Department of Medicine, Division of Endocrinology, Helsinki University Central Hospital, Helsinki, Finland
8 Neuroscience Center, University of Helsinki, Helsinki, Finland
*Corresponding author. Tel: +358 9 47171965; E-mail: anu.wartiovaara@helsinki.fi
EMBO Molecular Medicine Vol 8 | No 11 | 2016 ª 2016 The Authors. Published under the terms of the CC BY 4.0 license1234
We have previously shown that in MM mice, ketogenic diet can
slow down progression of the disease and improve metabolic and
lipidomic parameters (Ahola-Erkkila et al, 2010). Encouraged by the
beneficial effects in mice, we performed a pilot study in PEO/MM
patients, as well as for age- and gender-matched voluntary controls
with ketogenic “modified Atkins diet” (mAD). We demonstrate that
mAD can dramatically modify the disease course of adult-onset MM
by inducing muscle damage, especially targeting respiratory chain-
deficient fibers. The patients recovered well and showed a moderate
long-term increase in muscle strength.
Results
Study subjects and the diets
Table 1 summarizes the study subjects and Fig 1A the study design.
All of the five patients had PEO, mild proximal muscle weakness,
and exercise intolerance. For every patient, two gender- and age-
matched, healthy voluntary controls were recruited (males, n = 6;
females, n = 4; age range: 35–61 years). Fig 1A summarizes the
study protocol. Normalized isocaloric standard diet (ND) was intro-
duced to all study subjects for 2 weeks, after which they were gradu-
ally switched to mAD for 4 weeks. The pre-diet carbohydrate intake
of PEO patients was 41–48% (control mean = 43%), 14–20% (18)
proteins and 27–38% (34) fats of the total calorie intake. During
mAD, study subjects increased their protein and fat intake and
reduced gradually carbohydrate intake to 3–9% (Table EV1 and
Fig EV1A). The intake of saturated, monounsaturated, and polyun-
saturated fats all increased, but especially the two latter (Table EV1).
Modified Atkins diet induced acute muscle damage in all
PEO patients
The clinical status of the subjects was stable during their 2 weeks
on ND and the week of gradual transition to mAD, as documented
by clinical follow-up and the responses to questionnaires. The
plasma b-hydroxybutyrate levels increased in all the study subjects,
indicating ketosis and good compliance to the study (Fig 1B).
However, after 3–4 days of full mAD all of the PEO patients experi-
enced similar, gradually progressing muscle symptoms: burning
sensation and pain in their leg muscles which was enhanced by
exercise. These symptoms ascended to the lower back muscles, and
then to the arms and neck. Patients also reported headache and
tiredness. At the time, serum analysis of all the patients showed a
progressive increase of serum CK, alanine aminotransferase, and
myoglobin values (Figs 1C and D, and EV1C). Plasma FGF21
concentrations did not significantly change after mAD, even after
2.5 years (Fig EV1B). Kidney function and serum creatinine concen-
trations remained stable. Because of progressive symptoms in all of
the five PEO patients, the trial was prematurely discontinued, with
the maximum duration being 11 days on mAD. The laboratory tests
and muscle biopsy samples were collected just before diet termina-
tion. The plasma CK and myoglobin concentrations decreased to
pre-diet levels within 2 weeks. The diet-associated muscle symp-
toms gradually attenuated, and 1 month after mAD, the subjective
and objective clinical status of the patients was comparable to the
pre-diet state.
All of the control subjects tolerated mAD well and had no muscle
symptoms or elevated plasma CK values, and they all continued the
diet for the full 4 weeks. However, their sampling scheme, including
the second muscle biopsy, was timed similar to their corresponding
patients. All patients and controls showed an increase in plasma
urea, indicating amino acid oxidation, and a slight reduction in
plasma triglyceride values, but cholesterol, glucose, and insulin
levels remained normal (Fig EV1D–H). These results indicate that
mAD causes subacute muscle damage in MM patients, independent
of the underlying genetic defect, but has no such effects for healthy
muscle.
Muscle fiber degeneration in PEO, especially in ragged-red fibers
Prior to mAD, the vastus lateralis muscle of PEO patients showed
typical MM findings in their ultrastructure, with enlarged mitochon-
dria containing distorted or concentric cristae as well as paracrys-
talline and electron-dense inclusions (Fig 1E–G). After mAD, most
muscle fibers of PEO patients still had normal morphology, but
some fibers showed acute degenerative changes, with central
vacuoles containing cell debris surrounded by autophagosome
membrane-like structures (Fig 1H–K). A total of 0–4.5% of muscle
fibers were necrotic, with infiltrated macrophages (Fig 1I and K).
These individual dying muscle fibers often showed clear subsar-
colemmal mitochondria with paracrystalline inclusions (Fig 1J),
typical for RRFs. The short mAD showed no significant effects on
the overall histochemical COX activity, mtDNA copy number, or
mtDNA deletions in the patients’ muscle (Fig EV1I–K). These results
Table 1. Clinical and molecular characteristics of PEO patients.
Subjects Gender Age
Age of
onset Disease gene Main clinical symptoms
COX-negative
muscle fibers (%) RRFs (%)
Duration
of mAD
1 F 36 22 single mtDNA del ptosis, PEO, exercise intolerance 61 7 8 days
2 M 54 20 multiple mtDNA dela ptosis, PEO, exercise intolerance 11 4 9 days
3 M 52 30 multiple mtDNA dela ptosis, PEO, exercise intolerance 13 5 8 days
4 M 40 31 multiple mtDNA dela ptosis, PEO, exercise intolerance 22 4 11 days
5 F 62 30 single mtDNA del ptosis, PEO, exercise intolerance 27 3 4 days
Ctrls F = 4
M = 8
35–61 – – – – – 4 weeks
RRF, ragged-red fibers; F, female; M, male; del, deletions; mAD, modified Atkins diet.
aTwinkle duplication mutation of p.352–364.
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explain the increased CK and myoglobin values and the muscle pain
of the patients and indicate that mAD acutely and selectively
damages RRFs, the muscle fibers with most prominent RC
deficiency.
Increased caspase-3 activation and stalled autophagy in
PEO muscle
As muscle ultrastructure showed muscle fiber degeneration, we
immunostained the muscle sections for the proapoptotic cleaved
caspase-3, together with mitochondrial marker, to mark the affected
fibers with mitochondrial proliferation. Occasional muscle fibers
showing caspase-3 activation were detected in both pre- and post-
mAD in PEO, and the proportion of these fibers did not depend on
the diet, suggesting that caspase-3 activation and potential apoptosis
did not contribute to degenerative changes—indeed, the necrotic
fibers did not show increased amount of caspase-3 (Fig 2A and B).
These results indicated that mAD induced fiber degeneration in PEO
patients mostly by necrosis.
As some fibers showed central accumulations of autophago-
some-like structures in EM, we studied the amounts of p62, a
receptor for ubiquitinated cargo destined for autophagy (Bjorkoy
et al, 2005). Western blot analysis indicated increased amount of
p62 (two-tailed Mann–Whitney test, P = 0.0121; Fig 2C), suggest-
ing that the disease itself resulted in reduced autophagic flux,
leading to decreased receptor clearance. These results were
corroborated by immunohistochemical detection of p62, showing
p62 positivity especially in affected fibers with high mitochondrial
content (Fig 2D–G). However, the short mAD did not significantly
change p62 protein amounts in PEO patients’ muscle. To study
further the autophagy pathway, we analyzed the presence of an
autophagosome membrane component, microtubule-associated
protein 1 light chain 3B (LC3). This protein showed colocaliza-
tion with p62 in fibers with high mitochondrial content (Fig 2H)
and a mosaic-staining pattern in patient muscles compared to a
uniform pattern in healthy controls (Fig 2I). Only after mAD,
occasional fibers showed positive accumulation of LC3 (Fig 2I).
To clarify whether mAD-induced muscle damage led to satellite
cell activation, we analyzed pax-7 protein amount (Hawke &
Garry, 2001). ND PEO muscle samples showed increased
amounts of pax-7 (two-tailed Mann–Whitney test, P = 0.006),
suggesting basal satellite cell activation in MM, but the activation
was not further enhanced by the short mAD in the acute stage
of muscle damage (Fig 2C). These results suggest that mAD did
not increase autophagic flux or regenerative mechanisms in the
acute myolytic stage. Control individuals showed no changes in
any of the markers.
Mild improvement in muscle strength in PEO patients in
2.5-year follow-up
We asked whether the mAD-induced RRF lysis in our patients would
affect long-term muscle function, hypothesizing that the damage
might induce satellite cell fusion and regeneration. In 2.5 years of
follow-up, three out of four patients showed slight improvement in
muscle strength of leg and back muscles and in six-minute walking
distance (Figs 3A–C and EV2A–C). All of the patients had improved
lower extremity extension strength, and three out of four had
Figure 2. Mitochondrial myopathy patients show caspase-3 cleavage, satellite cell activation, and stalled autophagy, not affected by modified Atkins diet.
A, B Cleaved caspase-3-positive muscle fibers (*). PEO patient (P3) on normal diet (A; inset: caspase staining in healthy control individual) and after modified Atkins diet
(B). Arrowhead: caspase-negative necrotic fiber.
C Western blot analysis of autophagy receptor p62 and pax7 marking muscle satellite cell activation; left, blot; right, signal quantification in each patient.
D, E Immunohistochemical analysis of p62 and mitochondrial mass marker in consecutive sections. Asterisks indicate p62-positive fibers and corresponding affected
ragged-red fibers.
F, G Immunohistochemical analysis of p62 and mitochondrial mass marker after mAD; consecutive sections. Arrowheads indicate fibers that show p62 positivity but
have normal mitochondrial mass.
H p62- and LC3-positive ragged-red fibers (*) in PEO patient (P2) on normal diet.
I Muscle fibers showing granular LC3-positivity in PEO patient (P1) after mAD. Arrowhead indicates fiber that is enlarged in the inset figure.
Data information: Immunohistochemistry was performed on frozen sections. Scale bars: 50 lm (A–G, I) and 100 lm (H). Abbreviations: PEO, progressive external
ophthalmoplegia; ctr, healthy control individual; ND, normal diet; mAD, modified Atkins diet; Tom20, mitochondrial outer membrane transporter 20; p62, autophagy
receptor protein 62; pax7, paired box protein 7.
Source data are available online for this figure.
Figure 1. Modified Atkins diet induces ragged-red-fiber lysis in patients with mitochondrial myopathy.
A Modified Atkins diet (mAD) study protocol. PEO patients followed mAD for 4–11 days; the healthy control subjects for 4 weeks. Sampling times of controls were
matched with their corresponding PEO patients.
B–D Plasma beta-hydroxybutyrate (ketone body; B), creatine kinase (CK; C), and myoglobin (D) concentrations. Dashed line: upper limit of control range. The
individual patients are shown separately, and controls as mean with standard deviation (n = 10). Arrow: mAD endpoint in PEO patients; lines under graphs:
duration of mAD.
E–G PEO patient (P1) muscle before diet: (E) Ultrathin section of abnormal muscle fiber (arrowhead) with subsarcolemmal accumulations of mitochondria. Scale bar,
50 lm. (F) Electron micrograph of subsarcolemmal accumulation of abnormal mitochondria (same cell as in E). (G) Enlargement of the area marked in (F);
mitochondria with paracrystalline “parking lot” inclusions (arrow) and concentric cristae (asterisk). Scale bar, 1 lm.
H–J PEO patient (P1) muscle after mAD (H–J): (H) ultrathin section, lytic muscle fiber with centrally located organellar debris (arrow). Scale bar, 50 lm. (I) Electron
micrograph of a degrading muscle fiber with an invaded macrophage (arrow) (same cell as in H). (J) Enlargement of the fiber in (I): paracrystalline inclusions within
mitochondria (asterisk). Scale bar, 1 lm.
K Quantification of necrotic or apoptotic cells in PEO muscle from ultrathin sections. n.a., not available.
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improved static back muscle strength. The youngest patients
improved in all muscle strength tests. These results implied subtle
performance improvement, without any remarkable reported
changes in patients’ daily physical exercise, suggesting that the fiber
degeneration favoring RRFs may have affected the amount of sick
fibers and/or promoted regeneration with subtle long-term benefi-
cial consequences for muscle strength.
PEO patients are glycolytic and unable to switch
to beta-oxidation
The findings from the patients’ serum tests and muscle samples
suggested that upon low dietary carbohydrate content, RRFs were
unable to utilize ketones and fatty acids as their fuel and were
highly dependent on glucose as a carbon source. Accordingly, light
A
D E
F G
B C
Figure 3. Physiological and performance test results after mAD.
A–C Muscle strength and performance of PEO patients (P1-P4) on normal diet (ND) and after modified Atkins diet (mAD) (1 and 6 months and 2.5 years after initiation
of diet).
D–G Spiroergometry results from PEO patients and control subjects on normal diet (ND), as well as 1 and 6 months after mAD initiation. PEO patients had higher
serum lactate levels, and attenuated respiratory response to exercise. These effects were further enhanced after mAD and remained after 6 months of the study.
mAD increased patients’ serum ammonium (NHþ4 ) levels. Data are presented as mean  SD.
Data information: Abbreviations: Max, maximal exercise level; HbO2, oxidized hemoglobin; pCO2, partial pressure of CO2. Statistical analyses: Student’s t-test (two-tailed).
Asterisk above the data point: significant difference between PEO and controls. Asterisk below the data point: significant difference between ND and mAD within a group
(color-coded). *P < 0.05, **P < 0.01, ***P < 0.001.
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exercise stimulated a lactate increase in PEO patients in spiroergom-
etry test, which was further enhanced post-mAD (Fig 3D). The
blood ammonium values during ND were similar in PEO patients
and in controls, indicating equal usage of proteins as a fuel (Fig 3G).
Ammonium production in exercise remained slightly increased in
6 months of follow-up of PEO patients. They also showed slightly
decreased oxygen extraction from the blood (Fig 3E) and lower CO2
production (Fig 3F) after mAD, which was sustained in 6 months of
follow-up, suggesting that the switch to oxidative metabolism in
exercise was compromised. MRI and MRS analyses of PEO patients
showed increased liver and visceral adipose tissue (VAT) fat levels
as well as elevated intramyocellular lipid (IMCL) and extramyocellu-
lar lipid (EMCL) levels in the skeletal muscle. PEO patients also
had less double-bond lipids in their subcutaneous adipose tissue
(CH2/CH3). The short mAD did not, however, significantly affect
these parameters (Fig EV2D). mAD decreased slightly the amount of
subcutaneous adipose tissue (SAT) in both patients and controls
(ANOVA, P < 0.001) with slight weight loss (PEO: 1–4 kg; and
controls: 1–2 kg) despite the isocaloric diet design. These results
indicate that PEO is associated with accumulation of fats in the liver,
adipose tissue, and muscle and that PEO patients have a glycolytic
metabolic state.
Transcriptome consequences of mAD: suppression of
mitochondrial oxidative metabolism in PEO muscle, and
induction in healthy muscle
Global muscle transcriptomic analysis, comparing pre- to post-mAD
expression patterns in each patient, indicated widespread, highly
significant down-regulation of pathways linked to carbohydrate-
driven oxidative metabolism in PEO muscle. These changes spanned
from pyruvate dehydrogenase and acetyl-CoA synthesis to tricar-
boxylic acid cycle and oxidative phosphorylation (Fig 4A and B).
Consistent with the lytic changes, extracellular pathways associated
with degeneration and inflammation were induced. In controls,
however, mAD activated oxidative metabolism, up-regulating path-
ways of mitochondrial fatty acid transport and b-oxidation, protein
oxidation, and ketogenesis (Fig 4A and B). These pathways were
not induced in PEO, indicating that the transcriptional response
inducing lipid and ketone body utilization was lacking in MM
muscle. Our results also indicate that in controls, mAD strongly
induced a fasting-like response of oxidative metabolism.
mAD modifies plasma metabolome
Our quantitative targeted metabolomics analysis of 88 metabolites
of plasma indicated that PEO patients responded at the metabolome
level quite similarly to the controls (Figs 5A–D and EV3A and B).
However, mAD normalized some disease-associated metabolite
changes in PEO patient plasma, such as asparagine and alanine, the
latter being a known biomarker for mitochondrial disease (Fig 5A)
and xanthine (Fig 5D). In both patients and controls, mAD
increased significantly the levels of branched chain amino acids
(BCAAs) valine, isoleucine, and leucine (Fig 5A and B). Creatine
amount was increased in PEO patients’ plasma and further
increased after mAD both in PEO patients and in controls, which
together with decreased precursors (glycine, arginine, and guanidi-
noacetic acid) and increased creatine:creatinine ratio suggested
increased creatine synthesis, thereby increasing availability of high-
energy phosphates buffering ATP synthesis (Figs 5 and EV3A).
Purine breakdown products such as xanthine and cAMP, as well as
levels of the precursor glutamine, decreased after mAD. Similarly
decreased was another purine derivative, allantoin (Fig 5D), which
is produced non-enzymatically from uric acid by reactive oxygen
species (Grootveld & Halliwell, 1987). Pyrimidine pathway interme-
diates such as 2-deoxyuridine were increased after mAD in patients
and controls (Fig 5D), potentially replenishing the TCA cycle. Taken
together, these results indicate that mAD modifies considerably the
metabolism of both PEO patients and healthy controls, boosting the
energy carrier pool and utilizing alternative energy sources such as
BCAAs. The similar major metabolic changes in PEO patients and
controls suggested that the metabolic inflexibility was pronounced
only in affected muscle fibers, which are unable to oxidize non-
glucose carbon sources even if glucose was low.
Mice do not show a similar acute response to high-fat diet
The patient trial reported here was based on our previous mouse
study (Ahola-Erkkila et al, 2010): Deletor with MM (carrying the
same Twinkle mutation as our patients 2–4) showed significantly
delayed progression of MM after ketogenic diet (KD) of 10 months.
Because of the unexpected acute adverse response of the PEO
patients to the diet, we asked whether the mice also had an acute
response of muscle degeneration, which had remained undetected,
followed by improvement. Here, we applied 1 week of ketogenic
diet to Deletor mice. We detected a clear increase in plasma ketone
levels in these mice (P-OHButyr ND 0.19  0.06 mmol/l and KD
0.78  0.14 mmol/l), but found no signs of muscle degeneration,
neither by histological examination nor by blood analysis of CK
values (ND 436  386 U/l and KD 137  76 U/l). This result indi-
cated that mice and humans with MM have different responses to
high-fat, low-carbohydrate diet, indicating species-specific flexibility
in coping with mitochondrial dysfunction and changing diets.
Discussion
Mitochondria are the cellular hub for nutrient oxidation and contri-
bute also to cellular biosynthetic reactions, linking nutrient intake to
cellular energy metabolism and growth (Nikkanen et al, 2016).
However, the effects of different diets for mitochondrial disease
progression are unexplored. We report here a pilot study enrolling
PEO patients and healthy control subjects on a high-fat, low-
carbohydrate modified Atkins diet. mAD resulted in a uniform
response with subacute progressive damage of muscle fibers,
especially RRFs, in all of our MM patients, regardless of their geno-
type or age. The finding is important, as it (i) indicates directly that
a diet can modify mitochondrial disease progression; (ii) suggests
that a short mAD could decrease RRF number in a wide range of
skeletal muscles; and (iii) shows that Atkins diet—a common
weight-loss method—may cause acute muscle damage in a specific
population subgroup, raising the question whether an extreme
dietary scheme could contribute to manifestation of subclinical MM.
Our patients reached mAD-induced ketosis similarly as the
controls and showed increased serum BCAAs and other alternative
energy transducing pathways, indicating partially normal metabolic
EMBO Molecular Medicine Vol 8 | No 11 | 2016 ª 2016 The Authors
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Figure 4. Transcriptomic analysis of PEO muscle, before and after mAD.
A Most significantly altered transcriptomic pathways in PEO muscle (n = 4) and in control subjects muscle after mAD (n = 8). Blue color represents down-regulated and
red color represents up-regulated pathways.
B Genes, the expression levels of which formed the pathway results in (A). Statistical test: Benjamini-Hochberg multiple testing.
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response to low-carbohydrate diet of PEO patients. An increase in
plasma BCAA levels has been reported as a response to high-protein
diet in a study with human subjects with isocaloric diet design (Chiu
et al, 2014). However, the subacute degenerative response of RRFs,
“selective rhabdomyolysis”, and widespread down-regulation of the
whole mitochondrial oxidative pathway expression indicated that
RRFs are especially dependent of carbohydrates and are not able to
oxidize ketones, amino acids, or lipids for ATP production. Indeed,
MM patients accumulate lipids, especially inside RRFs, which is a
typical diagnostic finding for the disease. Our MRI data verified a
significant accumulation of fat in the patients’ muscle and liver.
Lipid oxidation is strictly controlled by redox status, especially
NADP/NADPH ratio, and reduced availability of NAD+, demon-
strated in MM mice (Khan et al, 2014), could underlie the metabolic
block.
Iatrogenic induction of muscle degeneration has been suggested
as a therapeutic strategy for MM patients carrying primary hetero-
plasmic mtDNA mutations (Clark et al, 1997). The rationale of this
idea is based on the finding that muscle satellite cells do not carry
mtDNA deletions, and their activation by damage would induce
their fusion to existing muscle fibers, replenishing them with wild-
type mtDNA. To purposefully induce muscle damage, previous
reports utilized bupivacaine hydrochloride injections to patient
muscle (Clark et al, 1997) or strenuous exercise (Taivassalo et al,
1999; Murphy et al, 2008). Our short dietary intervention of
1–1.5 weeks turned out to be an efficient way to stress the meta-
bolism of the whole-body musculature of MM patients, especially
targeting the damage to the most affected RRFs. This raised the
question whether such an induction could actually be beneficial
by inducing satellite cell fusion. We did not find signs of satellite
cell activation in the acute lytic phase, but the improving muscle
strength in all patients after 2.5 years, especially in the youngest
patients, suggests that satellite cell induction could occur in the
recovery phase.
Our patients with either single or multiple mtDNA deletions, that
is, sporadic or secondary mtDNA mutations, responded strikingly
uniformly to mAD, both qualitatively and chronologically. The
symptom progression, ascending from lower extremities to back
muscles, arms, and neck muscles, was similar in all, as was the
timing of the lytic response, based on increase of serum CK and
myoglobin. The remarkable similarity of the responses despite their
different genetic backgrounds suggests a uniform molecular patho-
physiology leading to manifestation of MM/PEO. Mitochondrial
disorders typically manifest with variable phenotypes, even in
patients with the same genetic lesion. Our findings emphasize the
importance of phenotypic uniformity of mitochondrial disease
patient groups in therapy trials in general—a factor perhaps more
important than uniformity of genotypes.
No knowledge of mAD effects in muscle exists, despite it being a
popular weight-loss scheme in the normal population and also used
in treatment of severe childhood epilepsies and mitochondrial ence-
phalopathies (for a review, see Sharma & Jain, 2014) (Panetta et al,
2004; Kang et al, 2007; Joshi et al, 2009). These case reports have
shown a decreased epileptic attack frequency during ketogenic diet,
but the diseases have progressed typically with a fatal course,
rendering the results of the true effects inconclusive. Typically,
mAD effects on muscle enzymes were not reported, even when used
in childhood mitochondrial disease. Our results suggest that CK
should be followed up when utilizing high-fat, low-carbohydrate
diet in treatment of mitochondrial disorders.
Our previous study on Deletor mice with MM demonstrated that
long-term high-fat, low-carbohydrate diet strongly induced mito-
chondrial biogenesis and cured the ultrastructural changes of MM
(Ahola-Erkkila et al, 2010). The Deletors mimic PEO patients in
having COX-negative, SDH-positive muscle fibers, although their
RRFs do not carry paracrystalline inclusions (Tyynismaa et al,
2005). Therefore, the acute response of our PEO patients in a similar
study was unexpected. We here performed a short-term ketogenic
diet for Deletor mice, to ask whether the mice had a similar acute
response that had remained undetected. However, no signs of
muscle degeneration or CK elevation were found in Deletors. These
findings indicate that the flexibility of mouse muscle to adapt to dif-
ferent diets is greater than in humans, even when suffering from
mitochondrial myopathy. Furthermore, the results emphasize the
importance of small pilot trials to follow promising treatment results
in mouse models.
mAD has been suggested as a treatment for obesity and T2D (for
a review, see Paoli et al, 2013). Our study did not indicate negative
side effects in healthy subjects. The transcriptome assay indicted
mitochondrial biogenesis induction and boosted oxidative phospho-
rylation. Control subjects showed a rapid metabolic shift to ketosis,
induction of oxidative metabolism in the muscle, and secretion of
alternative energy sources in the blood. However, a long-term
significant increase in plasma BCAA levels could be a risk factor for
developing insulin resistance and T2D (Newgard et al, 2009; Wang
et al, 2011; Newgard, 2012). The healthy subjects also showed
slightly reduced plasma triglyceride levels, but cholesterol, insulin,
or glucose levels remained unchanged. These findings are in agree-
ment with previous reports of low-carbohydrate diets in human
subjects (for a review, see Naude et al, 2014).
In conclusion, our results indicate that nutrition can drastically
modify progression of MM and that RRFs are dependent on
Figure 5. Metabolomic analysis of plasma on normal diet and after mAD.
A PEO patients, relative amino acid levels on normal diet (PEO), immediately after finishing mAD (PEO_mAD), and 1 month after mAD.
B Control subjects, relative amino acid levels on normal diet (Control) and immediately after finishing mAD (Control_mAD).
C Relative values of plasma metabolites in the creatine pathway, compared to controls on ND. Right: illustration of major metabolites and pathway of creatine
synthesis.
D Relative values of plasma purine and pyrimidine degradation pathway intermediates, compared to controls on ND. Right: illustration of major metabolites and
synthesis of pyrimidines and purines.
Data information: Values in all charts represent mean of relative values to untreated controls mean (dashed line)  SEM. Statistical analyses: Student’s t-test
(two-tailed). *P < 0.05, **P < 0.01, ***P < 0.001. Blue, decrease after mAD in PEO; red, increase after mAD in PEO. Abbreviations: GAA, guanidinoacetic acid; SAM,
S-adenosylmethionine; SAH, S-adenosylhomocysteine; MTHF, methyltetrahydrofolate; DHF, dihydrofolate; dUMP, deoxyuridylate; dTMP, deoxythymidylate; dU,
2-deoxyuridine; AIBA, aminoisobutyric acid; cAMP, cyclic adenosine monophosphate; GMP, guanosine monophosphate; IMP, inosine monophosphate; CK, creatine kinase.
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carbohydrate supply. Furthermore, our results show that mAD may
induce muscle cell damage in a small population group with
subclinical mitochondrial disease. Based on our results, muscle
symptoms and CK values should be closely monitored if low-
carbohydrate diet is used as treatment for mitochondrial disease
patient. The uniform response of our PEO patients to mAD indicates
existence of a yet-unknown metabolic block in adult-onset MM. The
exciting potential of dietary intervention as a treatment of MM/PEO,
aiming to target and reduce the number of RRFs, requires further
investigation.
Materials and Methods
All of the subjects gave their written informed consent to participate
in the study. The study was undertaken according to the Helsinki
declaration. Helsinki University Hospital ethics review board
approved the study. National Animal Experiment Board, Finland,
approved animal work, and all experiments were done in accor-
dance with good practice of handling laboratory animals.
Diet
The subjects filled food diaries for 7 days prior to the diet study,
which was used as a basis to calculate their normal daily caloric
intake and to design the individual isocaloric diets of the trial.
Table EV1 and Fig EV1A describe the detailed diet compositions.
The subjects were first enrolled on standardized normal diet (ND)
for 2 weeks, after which they descended gradually to mAD: One
meal per day was changed into mAD. All subjects were to continue
on mAD for a total of 4 weeks.
Muscle strength and performance analyses
Muscle strength of the patients was analyzed before and after mAD
by Medical Research Council score (Hahn et al, 1996), grip strength
by Martin Vigorimeter, and isometric muscle strength with “Good
strength” analyzer (Metitur Oy, Finland) (Era et al, 1992), including
elbow flexion and extension, lower leg extension, and grip strength
on both sides. In addition, the patients were tested for balance
(standing with one foot), walking for 6 min, static strength of back
muscles, and repetitive strength of stomach and upper limb
muscles. In addition, a “muscle symptom score” was determined by
questionnaire, designed to assess the main symptoms of PEO
patients, and RAND-36 questionnaire was utilized to assess their
general quality of life (Hays et al, 1993). In “muscle symptom
score” questionnaire, patients were asked to score their muscle pain
in scores of “not at all, mild, moderate, greatly, very greatly” in
“rest, activity, numbness, muscle tiredness, muscle weakness,
muscle cramps”. Patients were also asked to use the same scoring
to identify the muscles that have symptoms “calf and leg, thigh,
upper limbs, back and body, neck, head, eyelids and muscles
moving of the eyes”.
Laboratory examinations
Laboratory examinations were taken after overnight fasting: blood
count, alanine aminotransferase, asparate aminotransferase,
glutamyl transferase, cholesterol, high-density lipoprotein, low-
density lipoprotein, triglycerides, creatine kinase (CK), lactate, pyru-
vate, creatinine, urea, FGF-21, glucose, insulin, ketones, and blood
gases. FGF-21 was analyzed using BioVendor human FGF21 ELISA
kit.
Spiroergometry
Spiroergometry with blood gas, lactate, and ammonium analysis
was performed as in Mustelin et al (2008). The initial workload was
30–40 W for patients, 40 W for control women, and 50 W for
control men. HbO2, pCO2, lactate, and NH
þ
4 concentrations were
determined during rest, light exercise, and maximum exercise, as
well as 2, 4, 6, 10, 20, and 30 min after exercise.
Magnetic resonance imaging (MRI) and spectroscopy (MRS)
MRI/MRS experiments were performed on a 3.0-Tesla clinical
imager (Verio; Siemens). Point-resolved spectroscopy (PRESS)
sequence was used for hepatic MRS. Liver spectra were analyzed
by jMRUI v3.0 software, with the AMARES algorithm (Vanhamme
et al, 1997), and fat content was expressed as 100× methylene
intensity divided by the sum of methylene and water intensities.
Abdominal MRI was analyzed from 8 cm above to 8 cm below
the L4/5 lumbar intervertebral disks. Visceral (VAT) and subcuta-
neous (SAT) fat areas were determined using a region growing
method in SliceOmatic v4.3 image analysis program (Tomovi-
sion). Muscle MRI was analyzed from the middle of the soleus
muscle. The intensities of intramyocellular lipids (IMCL),
extramyocellular lipids (EMCL), and creatine (Cr) signals were
determined from water-suppressed spectra using LCModel v6.3
software. IMCL and EMCL contents were expressed as ratio to Cr
intensity.
Muscle sampling and histological analysis
A Bergstro¨m needle biopsy from vastus lateralis muscle was taken
before and after mAD (Fig 1A). The muscle samples for DNA, RNA,
and protein analyses were snap-frozen in liquid nitrogen, and
samples for histology were snap-frozen in liquid nitrogen-cooled
isopentane. All samples were stored at 80°C. Muscle samples for
electron microscopy (EM) were fixed in glutaraldehyde. Eight-
micrometer-thick frozen muscle sections were tested for cytochrome
c oxidase (COX)/succinate dehydrogenase (SDH) activities by stan-
dard histochemical activity assay. A total of 250–300 cells per
patient were counted to assess COX-negative/SDH-positive cells.
Immunohistochemistry was performed on 8-lm frozen sections for
p62 (dilution 1:500, Santa Cruz Biotechnology, #sc-28359/D-3),
cleaved caspase-3 (1:150 dilution, Cell Signaling, #9664), LC3 (1:50
dilution, nanoTools Antiko¨rpertechnik GmbH & Co. KG, #0231-100/
LC3-5F10), and mitochondrial marker antigen (dilution 1:10,
Biogenex, #MU213-UC/clone 113-1). Peroxidase stainings were
done with VECTASTAIN Elite ABC HRP Kit (Vector Laboratories)
for caspase and LC3 and with Multimer kit Ultraview Universal DAB
detection system (Ventana Medical Systems). Transmission electron
microscopy sample preparation and analysis was done as previously
described (Ahola-Erkkila et al, 2010). A total of 70–190 cells per
patient were counted from ultrathin sections, stained with toluidine
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blue, to determine the proportion of muscle fibers showing signs of
cell death.
RNA analysis
Total muscle RNA was extracted with standard TRIzol and chloro-
form method and purified with RNA purification kit (RNeasy;
Qiagen). A total of 250 ng of total RNA from four PEO patients and
eight controls was used for global gene expression analysis on the
HumanHT-12 v4 Expression BeadChip (Illumina) with TotalPrep
RNA Labeling Kit (Ambion). Chipster v2.1.0 software was used for
quantile normalization (http://chipster.github.io/chipster/). Data
were further filtered by coefficient of variation (standard deviation/
mean; 50% of all present genes were filtered out). To determine the
differently expressed genes between PEO or controls on ND and
after mAD, paired empirical Bayes statistical test was applied
together with the Benjamini–Hochberg P-value adjustment method.
For further analysis, the transcripts with adjusted P-value < 0.05 for
differential expression between PEO on standard diet and PEO on
Atkins diet were selected regardless of fold change and subjected to
pathway analysis using Ingenuity Pathway Analysis (IPA; Ingenu-
ity Systems; www.ingenuity.com). All genes with log2 fold change
> 0.26 and < 0.26 regardless of adjusted P-value between controls
on standard diet and controls on Atkins diet were used for IPA.
DNA analysis
DNA was extracted from the muscle samples using standard
phenol–chloroform extraction and ethanol precipitation and mtDNA
copy number was analyzed by qPCR, with primers from the mtDNA
gene for 12S rRNA and nuclear gene for amyloid-beta precursor
protein (APP), as previously described (Tyynismaa et al, 2012).
mtDNA deletion analysis was done using a quantitative PCR method
and the primers described in He et al (2002) with iQTM Custom
SYBR Green Supermix (Bio-Rad).
Protein analysis
Protein extracts were separated in 12% SDS–gel electrophoresis,
using antibodies against p62 (dilution 1 lg/ml, Abcam, ab56416)
and pax7 (dilution 1 lg/ml, Abcam, ab34360). Beta-tubulin anti-
body (dilution 1:1,000, Cell Signaling Technology, #2128) was
used as a loading control, and membranes were imaged using
Bio-Rad ChemiDocTM XRS+ with Image Lab software.
Metabolomic analysis
Plasma was separated immediately after sampling and stored at
140°C. Metabolites were analyzed with ACQUITY UPLC-MS/MS
system (Waters Corporation) as in Khan et al (2014). The column
was 2.1 × 100 mm Acquity 1.7um BEH amide HILIC column and
the detection system Xevo TQ-S tandem triple-quadrupole mass
spectrometer (Waters Corporation). In order to analyze differences
among groups, univariate analysis T-test2 was performed on auto-
scaled data. In order to explain the separation among groups, unsu-
pervised multivariate analysis, principal component analysis (PCA),
was performed. Non-transformed data were mean-centered and
autoscaled. Five components were used in all the PCA models.
Dendrogram was plotted on normalized data using Ward’s linkage
clustering algorithm and Pearson’s correlation similarity measure
and visualized as heatmap.
Short-term ketogenic diet for Deletor mice
Twenty-month-old male Deletor mice (Tyynismaa et al, 2005),
littermates in congenic C57Bl6 background, were randomized and
fed ketogenic or normal diet as in Ahola-Erkkila et al (2010) [keto-
genic diet n = 5, normal diet n = 3; diets: high-fat diet D05052004
(89.5 kcal% fat, 0.1 carbohydrate, 10.4 protein); control diet
D05052002 (11.5 kcal% fat, 78.1 carbohydrate, 10.4 protein;
Research Diets Inc.)] for 7 days, after which the animals were
fasted for four hours and then killed and blood was collected by
cardiac puncture. Serum samples were analyzed for CK and ketone
bodies, to assess muscle damage and success of the diet. Quadri-
ceps femoris muscle samples were fixed in glutaraldehyde and and
ultrathin sections were stained with toluidine blue and analyzed
by light microscope to assess cell death as in Ahola-Erkkila et al
(2010). Samples were numbered to ensure blinding of the investi-
gator.
Expanded View for this article is available online.
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The paper explained
Problem
Mitochondrial myopathy is a progressive genetic disorder with no
treatment. Animal studies suggested that ketogenic high-fat, low-
carbohydrate diet ameliorates the disease.
Results
Five adult patients with mitochondrial myopathy followed a high-fat,
low-carbohydrate “modified Atkins” diet, which resulted in progressive
muscle pain and signs of muscle damage in all patients within
2 weeks. This diet especially caused lysis of the ragged-red fibers
(RRFs), the hallmarks of mitochondrial myopathy. Such changes were
independent of patient genotype. The changes were accompanied by
subtle improvement of muscle strength in a 2.5-year follow-up.
Healthy subjects did not show such changes.
Clinical impact
mAD can induce muscle damage in mitochondrial disease patients.
The specific targeting of RRFs indicates a potential to decrease RRF
number by short dietary intervention. Evidence suggests that an
Atkins diet could provoke muscle damage in a population subgroup,
that is, people with subclinical mitochondrial disease.
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